PNH is characterized by expansion of one or more stem cell clones with a PIG-A mutation, which causes a severe deficiency in the expression of glycosylphosphatidylinositol (GPI)-anchored proteins. There is evidence that the expansion of PIG-A mutant clones is concomitant with negative selection against PIG-A wild-type stem cells by an aplastic marrow environment. We studied 36 patients longitudinally by serial flow cytometry, and we determined the proportion of PNH red cells and granulocytes over a period of 1-6 years. We observed expansion of the PNH blood cell population(s) (at a rate of over 5% per year) in 12 out of 36 patients; in all other patients the PNH cell population either regressed or remained stable. The dynamics of the PNH cell population could not be predicted by clinical or hematologic parameters at presentation. These data indicate that in most cases the PNH cell expansion has already run its course by the time of diagnosis. In addition, since in most cases no further expansion takes place, we can infer that the tendency to overgrow normal cells is not an intrinsic property of the PNH clone.
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by the presence in the patient's blood, together with normal cells, of a clonal 1 population of red cells with hypersensitivity to complement, resulting in intravascular hemolysis. This abnormality stems from a deficiency in the GPI-linked complement inhibitor CD59; 2 this in turn is due to a defect in the synthesis of the GPI anchor, which is necessary for the posttranslational modification and expression of CD59 and of a host of other membrane proteins, called the GPI-anchored proteins (reviewed in Ref 3 and 4) . This phenotype is the consequence of an acquired somatic mutation in a stem cell in the X-linked PIG-A gene, which encodes an essential enzyme in the GPI synthetic pathway. [5] [6] [7] While hemolysis in PNH is thus explained, the mechanisms promoting the expansion of the PNH clone have yet to be elucidated. Populations (0.002%) of PIG-A mutant cells have been demonstrated in normal individuals. 8 This indicates that PIG-A mutations themselves are not the causative factor in clonal expansion and that in PNH patients the expansion must be of 3-5 orders of magnitude. The epidemiologic association between PNH and acquired aplastic anemia (AA) 9 ,10 suggests a common pathophysiology, and it has been postulated that an aplastic marrow environment selectively favors PNH stem cells, conferring to them a growth and/or survival advantage. [11] [12] [13] Indeed, hematopoietic progenitors are decreased, 14 Correspondence: L Luzzatto, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi 10, 16132 Genova, Italy; Fax: +39 010 355573; e-mail: lucio.luzzatto@istge.it and cytopenias respond to immunosuppression in PNH patients 15 as in AA. Recently, oligoclonal T cell expansions have been identified in PNH patients, further supporting this model. 16 PNH also bears some resemblance to myelodysplastic syndrome (MDS). For example, we have recently demonstrated significant morphologic dysplasia, a cytogenetic abnormality, or both in the marrows of about half of PNH patients. 17 Since PNH clones have been identified in 10% to 25% of patients with a diagnosis of MDS, flow cytometry aiming to identify such clones is increasingly becoming part of the work up of MDS. [17] [18] [19] As in MDS, evolution of PNH to leukemia is possible (reviewed in Ref. 20) , although with a much lower frequency. Conversely, MDS bears some similarity to AA and PNH in that some MDS patients will also respond to immunosuppression. 18, 21 If expansion of the PNH cell population takes place by virtue of selection in favor of the PIG-A mutant clone(s) in an aplastic environment, this mechanism might or might not still operate after the PNH cell population is detected. 12 If it does, then the PNH cell population would continue to expand; if it does not, then the PNH cell population would remain stable or perhaps even regress, thanks to relaxation of selection. In contrast, if the mechanisms of clonal expansion were due to an intrinsic growth advantage of the PNH cell population, one would expect to see continuing expansion of these populations in all cases. To address this question further, we have studied quantitatively 36 patients with PNH cell populations longitudinally for up to 6 years.
Materials and methods

Patient selection and characteristics
We have included patients found to have a PNH cell population by flow cytometry between 1995 and 2001 for whom repeat samples were available over a period of at least 1 year. Samples were referred from patients with aplastic anemia, hemolysis, thrombosis, or a prior diagnosis of PNH after obtaining informed consent.
Of 362 patients referred, we identified a PNH population in 88. In 36 patients, we were able to obtain follow-up samples over a period of 1 to 5.9 years (median 2.2 years). In five patients, for either the initial or subsequent data points, the estimation of the proportion of PNH red cells was affected by frequent red cell transfusions; for these patients, data from the granulocytes but not the red cells is included in the analysis that follows. For seven patients, data on the proportion of PNH granulocytes was not included in the analysis of temporal trends because there was either only one data point, or the values were not above the threshold for detection (see Results).
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Flow cytometry
Flow cytometry was performed using the following antibodies: anti-CD59-FITC, igg2a-FITC isotype, and anti-CD16-FITC (RDI, Flanders, NJ, USA), and anti-CD24-FITC (Pharmingen, San Diego, CA, USA). For red cell analysis, 3 l of whole blood was incubated in 50 l of phosphate buffered saline (PBS) on ice with 10 l of anti-CD59 or isotype antibody for 30 min. To avoid artefactual false positive results, care was taken to ensure that the entire sample came in contact with the antibody. The cells were then washed in PBS and fixed with 1% paraformaldehyde. To analyze granulocytes, 50 l of whole blood was incubated with 10 l of anti-CD59-FITC, 20 l of anti-CD24-FITC, or 1 l of anti-CD16-FITC on ice for 30 min. The red cells were then lysed with a Coulter (Fullerton, CA, USA). Immunoprep kit and the sample was centrifuged, and washed in PBS, and resuspended in PBS with 1% paraformaldehyde prior to analysis. Samples were analyzed on a Becton Dickinson (Franklin Lakes, NJ, USA) FACScan. Red cells and granulocytes were identified by forward and side scatter characteristics and the data analyzed with CellQuest software. In order to identify rare PNH red cells, at least 100 000 gated events were collected.
PNH was diagnosed based on the finding of a bi-modal distribution using CD59 for the red cells or a panel of antibodies for the granulocytes. The gates were defined based on the isotype antibody staining and were adjusted to intersect the nadir of the histogram curve between the normal and PNH populations. In patients with a tri-modal red cell distribution curve (indicating the presence of PNH II as well as PNH III cells) we report both abnormal populations together as representing the overall PNH population. We excluded data points where severe granulocytopenia or extensive red cell transfusions precluded interpretation. For the granulocytes, we did not include in the analysis temporal trends of patients where the initial and final proportion of PNH cells were both Ͻ3%.
Analysis of temporal trends
We graphed the proportion of PNH red cell and granulocytes as a function of time. For each time course curve, the mean slope was calculated as follows: slope = (final value − initial value) Ϭ time (in years). This slope therefore represents the change over time in absolute terms. We also calculated a 'fractional change' ratio, the final value Ϭ the initial value, which measured the change in relative terms. For 10 patients who received ATG for whom adequate data points were available, we calculated a 'slope of the total PNH cells' by calculating the difference in the absolute number of PNH cells (the red blood count × % PNH red cells and the ANC × % PNH granulocytes) at the time of ATG treatment and at last followup Ϭ time (in years) between the two data points.
Results
Sensitivity of the method
In order to determine the reliability of flow cytometry analysis for the detection of extremely small PNH populations, we carried out a number of baseline studies. (1) Using anti-CD59 to estimate the proportion of negative cells, the mean +3 standard deviations in normal donors was Ͻ0.04% for red cells and Ͻ2% for granulocytes. (2) After making artificial dilutions of PNH red cells in normal red cells, we could identify a CD59-negative population as small as 0.05%. (3) In blood samples from three patients with extremely small PNH red cell populations (0.22% to 0.76%), practically no PNH cells could be seen by flow cytometry after treatment with acidified serum in the HAM test, confirming the specificity of the analysis for identifying such small clones (see Figure 1) . (4) In repeat samples, PNH red cell populations as small as 0.1% were reproducibly demonstrated in patients (see Figure 2a) but not in normal donors. Therefore, to define a sample as having an abnormal PNH cell population we used a conservative cut off value of 0.1% for red cells and 3% for granulocytes.
Patient characteristics
The patients fell into two general groups: those presenting with AA with a small PNH clone (AA/PNH) and those with 'classic PNH' (Table 1) . 'AA/PNH' samples were from patients with hypocellular marrows and cytopenias prior to administration of ATG, and had PNH red cell populations at the start of the study of Յ3%. 'Classic PNH' samples were from patients who generally presented with hemoglobinuria and/or a history of thrombosis, cellular marrows, and PNH red cell population of Ն7%. None of our patients developed leukemia or excess blasts. Two-color flow analysis of red cells before and after exposure to activated complement confirms the ability of the single antibody flow assay to detect very small PNH populations. Red cells from a patient with aplastic anemia: 0.5% of the red cells did not exhibit fluorescence after staining with the antibody, CD59-FITC. To verify the specificity of this test, red cells were incubated in the HAM test with (a) heat inactivated or (b) not heat inactivated type AB human serum. Cells were then analyzed by flow cytometry after staining using antibodies specific for CD55, CD59 and glycophorin A as previously described. 8 In panel a, 0.76% of the red cell population (lower right quadrant) do not express the GPI-anchored proteins CD55 or CD59 but do express the transmembrane protein glycophorin A. This population is no longer evident in panel b, indicating that it has been lysed in the HAM test. This assay confirms the specificity of the single antibody test using anti-CD59-FITC to detect PNH red cell populations of less than 1%.
Fate of PNH cell populations over time
Figure 2
Flow cytometric analysis reproducibly demonstrates PNH cell populations, with little change in the proportion of PNH cells over time for most patients. Percentage of PNH red cells (a) and granulocytes (b) as a function of time. The vertical axis is on a logscale with a change in scale at 10%.
however, there was significant expansion of the PNH cell population, with slopes for the red cell or granulocyte time course being Ͼ5.0 for 12 of 36 patients. A similar pattern of distribution was seen when analyzing the fractional change values, ie the change in the size of the population relative to its initial size.
There was no correlation between the calculated slope or the fractional change and the initial size of the PNH cell population. The slope and the fractional change did not correlate with the patient's age, peripheral blood counts, marrow cellularity, or history of thrombosis. Because immunosuppression with ATG is sometimes used in the management of PNH, it was of special interest to determine the effect of this treatment on the size of the PNH population. Given that peripheral blood counts may increase in patients responding to immunosuppression, we analyzed absolute figures (the red blood count × % PNH red cells and the ANC × % PNH granulocytes) as well as percentages. In 10 patients with adequate data points pre-and post ATG, nine of these had a significant
Leukemia
Figure 3
Analysis of the slopes of the curves in Figure 2 reveals a clustering around the value of 0. Negative values represent a decrease and positive values an increase in the proportion of PNH cells. Thus, a PNH population that increases from 5% to 15% over 5 years would correspond to a slope of + 2.0, whereas a decrease from 15% to 5% over 5 years would correspond to a slope of response in terms of neutrophil count, platelet count, or both. The slope of the total PNH cells over time ( Figure 4) followed a distribution very similar to the slope of the relative values for the group overall ( Figure 3 ). This is in keeping with data recently published from another center.
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Discussion
In previous reports, three outcomes -stability, expansion, and regression of PNH clones -have been described. [22] [23] [24] [25] [26] [27] Here, we show that in a sizable series of patients the size of the PNH cell population is essentially stable over time. We also found that, compared to larger clones (such as those found in 'classic PNH'), small clones (such as those found in AA/PNH patients by highly sensitive flow cytometry) were no more likely to expand, even though there is greater potential for them to do so. Here, we discuss briefly some implications of these findings.
Pathophysiology
In order to reach the value of 0.1%, which we have adopted as our cut-off for a significant PNH cell population, this must have expanded by at least 2 orders of magnitude above the proportions seen in normal individuals. 8 Thus, we were not surprised to find that in some patients (about one-third), this expansion was still on-going. On the other hand, stability or even regression in the remaining two-thirds requires an explanation. In fact, smaller clones were as likely to remain stable or regress as larger clones: thus, the expansion of PNH clones often reaches a plateau both in 'AA/PNH' and in patients with 'classic PNH'.
Based on animal models (reviewed in Ref. 28) , and on human studies, 8 we know that PIG-A gene mutations are not sufficient for clonal expansion. Alternative possibilities include (1) possible mutations in other genes; (2) an abnormal marrow environment -which may result from auto-immunity -favoring the PNH clone. Our current findings support the latter rather than the former explanation. Indeed, if acquired mutations in tumor suppressor genes or oncogenes were driving the clonal expansion, one would expect to see this to continue until the bone marrow is completely taken over by the clone itself. Although we cannot rule out that this happens in exceptional cases, it is evident that PIG-A mutations do not necessarily lead to inexorable clonal expansion, even when they are associated with visible chromosomal abnormalities. 17 Our clinical findings are instead most consistent with the model of immunological selection in favor of PNH cells, 16, 29 which also explains the presence of multiple PNH clones in some patients. 30, 31 Auto-immune processes often wax and wane; if autoimmune selection in favor of the PNH clone wanes, one would expect to see clones that may be large but are no longer expanding, as we have observed. The lack of an intrinsic growth advantage of PNH clones is consistent with the fact that, unlike in leukemia or in MDS, bone marrow transplantation with non-myeloablative conditioning can cure PNH. 32 
Prognosis
Patients with a small PNH cell population (who usually presented initially with aplastic anemia, see the top section of Changes in the absolute number of PNH cells in 10 patients treated with ATG. As in Figure 3 , there is a clustering around the value of zero, indicating no significant change in most patients. Table 1 ), can probably be reassured: there is a low chance that, over a period of years, their PNH cell population will expand sufficiently to cause clinical hemolysis. This ought to be monitored periodically by serum lactate dehydrogenase levels and flow cytometry analyses on red cells. On the other hand, quantitation of PNH granulocytes by flow cytometry should be performed in patients with apparently small PNH red cell populations who are red cell transfusion dependent at presentation.
Treatment
Usually patients with PNH are treated with intensive immunosuppression (ATG plus cyclosporin A) when they are severely pancytopenic. 15, 33 In the sub-set of patients who have an expanding PNH cell population, there may be a rationale for using this approach to treat the presumed underlying mechanism (ie auto-reactive destruction of normal stem cells), even if they are not severely pancytopenic, because they may have an on-going auto-immune process. In this series we could not detect an effect of ATG on the time-course of the size of PNH population over time.
Conclusion
The majority of patients with PNH are in a steady state in which the proportion of hematopoiesis contributed by the PNH clone(s) is stable. The simplest interpretation of this finding is that in most patients, by the time of diagnosis, the autoimmune process that selects for PNH cells has either remitted or no longer discriminates between PNH and normal stem cells. In a minority of patients there is some expansion of the Leukemia PNH cell population, as though the selective process is still continuing. The outcome of ATG can be similarly interpreted. If the selective process is no longer active, we cannot expect much effect from ATG. In patients where the selective process is still active, ATG will cause relaxation of selection, in addition to improvement in the blood counts. Although there is no direct effect of ATG on the PNH cells, over the short term one would see halting of expansion and, in the long term, one may eventually see a decline in the PNH cell population due to senescence. This interpretation will have to be corroborated by follow-up of treated patients.
